Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review
| Autor: | Shashideep Singhal, Sury Anand, Manhal Olaywi, Taruna Bhatia |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
Cirrhosis Disease digestive system Gastroenterology Insulin resistance Glucagon-Like Peptide 1 Non-alcoholic Fatty Liver Disease Internal medicine medicine Humans Hypoglycemic Agents Transaminases Dipeptidyl-Peptidase IV Inhibitors Hepatology Liraglutide business.industry Venoms Fatty liver Sitagliptin Phosphate nutritional and metabolic diseases Triazoles medicine.disease digestive system diseases Fatty Liver Treatment Outcome Liver Sitagliptin Pyrazines Exenatide Steatohepatitis business Peptides medicine.drug |
| Zdroj: | Hepatobiliarypancreatic diseases international : HBPD INT. 12(6) |
| ISSN: | 1499-3872 |
| Popis: | Background Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum that ranges from simple steatosis to non-alcoholic steatohepatitis (NASH) and to cirrhosis. The recommended treatment for this disease includes measures that target obesity and insulin resistance. The present review summarizes the role of newer anti-diabetic agents in treatment of NAFLD. Data Sources PubMed, MEDLINE and Ovid databases were searched to identify human studies between January 1990 and January 2013 using specified key words. Original studies that enrolled patients with a diagnosis of NAFLD or NASH and involved use of newer classes of anti-diabetic agents for a duration of at least 3 months were included. Results Out of the screened articles, four met eligibility criteria and were included in our review. The classes of newer anti-diabetic medications described were dipeptidyl peptidase IV inhibitors and glucagon-like peptide-1 analogues. Conclusions Liraglutide and Exenatide showed improvement in transaminases as well as histology in patients with NASH. Sitagliptin showed improvement in transaminases but limited studies are there to access its effect on histology. Further studies are needed to support use of newer anti-diabetic medications in patients with NAFLD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect